ライフサイエンスコーパス: adverse reaction

1 ulocytosis is a potentially life-threatening adverse reaction.

2 -responsiveness (AHR) with minimal pulmonary adverse reaction.

3 All patients tolerated the drug without any adverse reaction.

4 One-fourth (n=170) had at least one adverse reaction.

5 reviously known to be a linezolid-associated adverse reaction.

6 ions of the mAb could be used to reduce such adverse reactions.

7 ety, assessed by the number and intensity of adverse reactions.

8 eports) were the 3 most frequently occurring adverse reactions.

9 ustained unresponsiveness and a reduction in adverse reactions.

10 Medicine to restore its surveys of reported adverse reactions.

11 he intended therapeutic effects and frequent adverse reactions.

12 matory lesions without serious infections or adverse reactions.

13 sensitivity, thrombocytopenia, and more rare adverse reactions.

14 , and the potential for irritation and other adverse reactions.

15 sily achievable by NUC therapy, with limited adverse reactions.

16 ons derived from their secondary effects and adverse reactions.

17 ode: drugs, protein targets, indications and adverse reactions.

18 nstitutes an important cause of food-related adverse reactions.

19 thways to predict new indications as well as adverse reactions.

20 efits, but have been associated with serious adverse reactions.

21 edure, and in a few cases potential systemic adverse reactions.

22 argeted to improve therapy while attenuating adverse reactions.

23 ssociation between, radiopharmaceuticals and adverse reactions.

24 complement inhibitors all recovered with no adverse reactions.

25 no changes in nutritional parameters and no adverse reactions.

26 men, recommended boosters, and potential for adverse reactions.

27 zinamide was responsible for the majority of adverse reactions.

28 ologic manifestations of the immune-mediated adverse reactions.

29 ure to detect potential rare vaccine-related adverse reactions.

30 ing of processed foods is mandatory to avoid adverse reactions.

31 h prediction and prevention of these serious adverse reactions.

32 and followed up for 3 months had no serious adverse reactions.

33 er antibiotics in patients with a history of adverse reactions.

34 cause of an increased risk of statin-induced adverse reactions.

35 isk factors" for failure, visual acuity, and adverse reactions.

36 sociations between drugs and their potential adverse reactions.

37 ocol restricting collection and reporting to adverse reactions.

38 the pharmacovigilance plan was restricted to adverse reactions.

39 peanut allergy may be limited by the risk of adverse reactions.

40 y specimens from 28 control subjects with no adverse reactions.

41 acotherapy, as well as to reduce caregivers' adverse reactions.

42 use of these drugs is associated with severe adverse reactions.

43 to determine the behavioral significance of adverse reactions.

44 ions, but does not induce FcgammaR-dependent adverse reactions.

45 l cancer, but are unsuccessful due to severe adverse reactions.

46 ry etiology of loiasis ivermectin-associated adverse reactions.

47 xis, and organ-specific and severe cutaneous adverse reactions.

48 erious adverse events, and implicated in few adverse reactions.

49 Myelotoxic effects were the main adverse reactions.

50 iseases, but also represent a major cause of adverse reactions.

51 SMC was well tolerated with no serious adverse reactions.

52 ted to ferumoxytol injection were considered adverse reactions.

53 rative and quantitative analysis of tramadol adverse reactions.

54 significant [a suspected unexpected serious adverse reaction]).

55 All systemic adverse reactions (0.8% of all injections in the verum g

56 doses in year 1, 15.4% were associated with adverse reactions: 0.04% were severe, and 0.08% subjects

57 There were no differences in serious adverse reactions (16 reactions in 14 participants recei

58 Fewer controls had adverse reactions (29 of 111 [26%]) than did participant

59 Six patients had no adverse reactions, 3 had minor bleeding, 6 required bloo

60 of 265 women reported at least one solicited adverse reaction: 39 (45%) of 87 women with HIV and low

61 d cephalosporin-associated serious cutaneous adverse reactions (95% CI, 0-1 in 217,291).

62 Sheffield NARCOS (National Adverse Reactions Advisory Service) investigates suspect

63 In conclusion, many patients experience mild adverse reactions after completing oral immunotherapy an

64 2 of 6069 children (16.2%), parents reported adverse reactions after food consumption in the online q

65 ntibiotic allergies and the association with adverse reactions after standard intravitreal antibiotic

66 l as between disease recurrence and scars or adverse reactions after surgery or radiation therapy.

67 cidence of influenza-like illness (ILI), and adverse reactions after vaccination.

68 In total there were 12 adverse reactions, all mild, reported by five participan

69 literature pertaining to recently discovered adverse reactions; all studies found PPIs are being over

70 uicide gene grants a mechanism of control of adverse reactions, allowing safe infusion after partiall

71 was also associated with significantly more adverse reactions and early study withdrawal.

72 formula B-FAHF-2 (BF2) ameliorates PN/TN OIT adverse reactions and enhances persistence of a tolerant

73 itivity is a major cause of severe cutaneous adverse reactions and is strongly associated with the HL

74 e trial was stopped early because of serious adverse reactions and limited evidence for seizure reduc

75 Adverse reactions and mechanistic changes were assessed.

76 irment of this enzyme leads to unanticipated adverse reactions and therapeutic failures; these reacti

77 ptimize dosage or to avoid a medication with adverse reactions and to prescribe an alternative therap

78 mise, treatment is frequently complicated by adverse reactions and, even when successful, has limited

79 ship is important in controlling resistance, adverse reactions, and cost.

80 antivenom, hampered by poor access, frequent adverse reactions, and cumbersome production/purificatio

81 nclude long treatment periods, high rates of adverse reactions, and lack of permanence of desensitiza

82 f alert clinicians in reporting of suspected adverse reactions, and the importance of internationally

83 salt pharmacokinetics, therapeutic effects, adverse reactions, and the present repurposing of these

84 ents who had ischemic events, who had severe adverse reactions, and who required life support were si

85 o be immediately life-threatening [a serious adverse reaction] and increased focal seizures and decre

86 ing (BW), Warnings and Precautions (WP), and Adverse Reactions (AR), where the severity of ADRs are i

87 orted as well as veterinarian-diagnosed food adverse reactions are on the increase.

88 associated anaphylaxis and serious cutaneous adverse reactions are rare compared with C difficile inf

89 mechanisms through which omalizumab induces adverse reactions are still unknown.

90 Serious adverse reactions are uncommon.

91 ring VIT, 11 (34%) cMCD patients experienced adverse reactions (ARs) (7% in controls), including 1 an

92 Cutaneous adverse reaction associated with entecavir has rarely be

93 ses in which there is a greater incidence of adverse reactions associated with certain antigens, such

94 ter studied, while they circumvented certain adverse reactions associated with FcgammaR engagement.

95 come measure was the frequency and nature of adverse reactions associated with the transfusion.

96 No serious adverse reactions associated with the use of convalescen

97 SMC was well tolerated with no serious adverse reactions attributable to SMC drugs.

98 red with vehicle, with no reports of serious adverse reactions attributable to the therapy.

99 xtremely well at classifying known causes of adverse reactions (AUC 0.92).

100 This modification is considered an adverse reaction, because it induces alterations of prot

101 was the primary end point, whereas rates of adverse reactions being a secondary outcome.

102 -tolerated with the most frequently reported adverse reactions being the local reactions in the oral

103 employed as a diffusion barrier, preventing adverse reactions between coflowing solutions.

104 % of the 18,165 doses were tolerated without adverse reactions beyond the oropharynx, with no severe

105 TXB2-hFc did not elicit any acute adverse reactions, bind, or deplete circulating reticulo

106 culated after 5 months of age, although mild adverse reactions can be more frequent, along with short

107 and can stimulate a range of immune-mediated adverse reactions-collectively known as drug hypersensit

108 ar 2, and 209 (12%) of 1673 in year 3 had an adverse reaction (compared with 216 [13%] of 1730, 380 [

109 ncompatibilities, aiming at the reduction of adverse reactions, cost and hospitalization period, and

110 ship between the radiopharmaceutical and the adverse reaction could not be determined.

111 t Reporting System and meaningfully cover an Adverse Reaction Database provided by Health Canada.

112 Self-reported food allergy and adverse reaction details, including anaphylaxis, were id

113 Only one patient had a severe adverse reaction, developing posttreatment liver failure

114 The prevalence of delirium, pain, anxiety, adverse reactions, duration of mechanical ventilation, l

115 Not all subjects experienced some adverse reactions during inhalation of SK-1211, all of w

116 Patients were monitored for adverse reactions during the dosing sessions and subsequ

117 cross validation scheme in which 10% of drug-adverse reaction edges were systematically deleted per f

118 immunosuppression due to increased risk for adverse reactions (eg, progressive vaccinia).

119 role of systemic innate immune activation in adverse reactions elicited by foods in FPIES.

120 n outcomes included anaphylaxis, allergic or adverse reactions, epinephrine use, and quality of life,

121 of Bos d 11 in baked muffins pose a risk for adverse reactions, especially in patients who have high

122 from the European Study of Severe Cutaneous Adverse Reactions (EuroSCAR; 1997-2001), we were not abl

123 radiologic manifestation of immune-mediated adverse reactions, even in asymptomatic patients.

124 antiviral drug abacavir, which causes severe adverse reactions exclusively in patients expressing the

125 as the proportion of participants developing adverse reactions following the primary vaccination and/

126 he acceptance, correlates of protection, and adverse reactions following vaccination in both young an

127 ucial for patients with peritonitis to avoid adverse reactions from a high concentration of gentamici

128 earning has the potential to predict unknown adverse reactions from current knowledge.

129 adherence and persistence and by recognizing adverse reactions from glaucoma medications and surgerie

130 al use, at recommended doses, is safe and no adverse reactions have been described.

131 Severe adverse reactions have been observed in individuals with

132 ials and mechanisms by which they may induce adverse reactions have not received sufficient attention

133 attenuate visceral pain, but concerns about adverse reactions have restricted their availability.

134 e study infusion was stopped early due to an adverse reaction in 5 participants receiving NAC [nausea

135 15 serious adverse reactions in 12 patients were reported; 12 of th

136 for myo/pericarditis did not detect cardiac adverse reactions in 382 study participants.

137 were very well tolerated, with only grade 1 adverse reactions in 5-10% of patients.

138 on immediate-type food allergy vs other food adverse reactions in companion animals, and compare this

139 The risk of adverse reactions in egg-allergic individuals should the

140 correlates of protection in males and reduce adverse reactions in females in an effort to increase ac

141 nging due to ivermectin treatment-associated adverse reactions in loiasis co-infected patients.

142 with penicillin procurement and concern with adverse reactions in patients with advanced disease rema

143 y contribute to the increased risk of statin-adverse reactions in patients with DM2.

144 the first few minutes of injection overcomes adverse reactions in pigs using two independent approach

145 benefit and those most likely to experience adverse reactions in response to a drug, and tailoring t

146 riences that was suggestive of low levels of adverse reactions in terms of family support and communi

147 The most common adverse reactions include headache, insomnia and nausea.

148 of PPI use with a wide range of neurological adverse reactions including, migraine, several periphera

149 cause potentially significant (albeit rare) adverse reactions, including agranulocytosis and hepatot

150 446 mg], P < .001), but treatment-associated adverse reactions, including hyperglycemia and hypertens

151 ministration of EMP-123 resulted in frequent adverse reactions, including severe allergic reactions i

152 Other adverse reactions, including weight loss, oxidative stre

153 combined with the extremely low incidence of adverse reactions, indicates the quality of these vaccin

154 I therapy has been limited by immune-related adverse reactions (irAEs) affecting multiple organ syste

155 ond favorably to treatment or experience and adverse reaction is an essential step toward development

156 The presence of immune-mediated adverse reactions is associated with a better response t

157 ne mechanism of ALP-induced severe cutaneous adverse reactions is poorly understood, and the T cell-r

158 ption of peanut and can eat the food without adverse reactions, known as sensitized tolerance.

159 There were no differences in adverse reactions leading to discontinuation of LTBI tre

160 sit compliance, transaminase elevations, and adverse reactions leading to discontinuation of LTBI tre

161 Shorter onset durations of mild adverse reactions (lymphadenitis and injection site reac

162 Adverse reactions (mainly hypotension, flushing, and hyp

163 s to be effective, and can be accompanied by adverse reactions, many patients face difficulties compl

164 R and MEK is frequently limited by cutaneous adverse reactions, most commonly acne-like eruptions.

165 Half experienced adverse reactions, mostly mild.

166 Participants without adverse reactions (n = 10) then received intravenous mor

167 We analyzed 233 BCG adverse reactions, namely regional lymphadenitis (33.9%)

168 cokinetics (PK) between patients and various adverse reactions necessitate improvement in delivery me

169 Serious adverse reactions necessitating hospitalisation occurred

170 921 placebo doses, 5.8% were associated with adverse reactions; none were severe.

171 17 serious adverse reactions occurred in 11 patients, and there was

172 Immune-mediated adverse reactions occurred in 27.8%, being most common i

173 Adverse reactions occurred in 6 patients (86%) and inclu

174 Adverse reactions occurred in a quarter of all patients,

175 Serious adverse reactions occurred only in the capivasertib grou

176 al neuropathy (CIPN) is a severe and painful adverse reaction of cancer treatment in patients that is

177 Ten children in the intervention group had adverse reactions of a minor nature.

178 here were 204 reports of radiopharmaceutical adverse reactions, of which 13 were considered invalid,

179 No suspected unexpected serious adverse reactions or severe adverse events related to va

180 whether peramivir affected outcome or caused adverse reactions other than rash.

181 For adverse reactions, our predictions were significantly en

182 ug demonstrated good integration and lack of adverse reaction over 28days.

183 y [WBC decrease (P = 0.04); gastrointestinal adverse reactions (P < 0.001)].

184 se escalation periods and has a high risk of adverse reactions, particularly in food allergy.

185 antigen (Ag) and carry a significant risk of adverse reactions, particularly in highly sensitized pat

186 HLA alleles associated with a range of these adverse reactions predominantly affecting the skin but a

187 symptoms; and the remaining five experienced adverse reactions preventing completion of dosing.

188 The observed adverse reaction rate to gadoteridol was lower than prev

189 hem, with high efficacy rate (98%) and a low adverse reaction rate when compared with oral administra

190 nd have been associated with relatively high adverse reaction rates.

191 Subjects with lower rates of adverse reactions, regardless of arm, experienced better

192 No participants had adverse reactions related to self-harm, suicidality, or

193 rticipant who received phenytoin had serious adverse reactions related to study treatment (hypotensio

194 Despite the widespread usage of FCs, adverse reactions related to their consumption, includin

195 There were no serious unexpected adverse reactions reported during the study.

196 We reviewed BCG-induced adverse reactions reported to Vaccine Injury Compensatio

197 Clinical presentations of BCG-related adverse reactions reported to VICP for the 2012-2017 bir

198 There were no serious adverse reactions reported.

199 tridium difficile infection, or drug-related adverse reactions requiring discontinuation.

200 (SJS) is a life-threatening severe cutaneous adverse reaction (SCAR), mainly caused by drugs.

201 ug hypersensitivity such as severe cutaneous adverse reactions (SCAR), including Stevens-Johnson synd

202 iotics are a major cause of severe cutaneous adverse reactions (SCARs).

203 Boxed Warning, Warnings and Precautions, and Adverse Reactions sections of the labels of 870 drugs.

204 Eight unexpected serious adverse reactions (six in the individual hypnotherapy gr

205 among patients who developed immune-mediated adverse reactions than in those who did not (68.2% vs. 3

206 radiologic manifestations of immune-mediated adverse reactions than in those without radiologic manif

207 erienced significantly fewer and less severe adverse reactions than OIT-only-treated mice (P<.01) dur

208 All active dosages resulted in more adverse reactions than placebo, which were mainly mild a

209 One unexpected, possibly related, serious adverse reaction that occurred 7 days after a 640 mug in

210 (DEC) treatment of loiasis is complicated by adverse reactions that are correlated with the number of

211 Next, a subset of adverse reactions that could be reliably detected in ano

212 tial to improve patient safety by predicting adverse reactions that were not observed during randomis

213 evaluated the occurrence of immune-mediated adverse reactions, their radiologic manifestations, and

214 In 59.1% of patients with adverse reactions, there were radiologic manifestations

215 esence of pollinosis (P = 0.004), history of adverse reaction to Bet v 1-associated food allergens (P

216 Drug-induced liver injury (DILI) is an adverse reaction to drugs or other xenobiotics that occu

217 uilding on previous EAACI position papers on adverse reaction to foods and three recent systematic re

218 o fevers induced by viral infection or as an adverse reaction to live-virus vaccines such as measles,

219 epatic ischemia/reperfusion (I/R) is a major adverse reaction to liver transplantation, hemorrhagic s

220 lerated the PET/MRI examination well, and no adverse reactions to (18)F-FTC-146 were reported.

221 arents (7.4%) and the reported prevalence of adverse reactions to additives (0.01-0.23%), which is hi

222 occurrence and risk factors associated with adverse reactions to DAT.

223 nt mechanism may be the predominant cause of adverse reactions to diclofenac.

224 Unknown adverse reactions to drugs available on the market prese

225 Thirty-four patients with a history of adverse reactions to food, GI tract symptoms, and birch

226 35% of the population modify their diet for adverse reactions to food.

227 international workgroup convened through the Adverse Reactions to Foods Committee of the American Aca

228 tify the mechanism of antigen specificity of adverse reactions to foods in FPIES.

229 The etiology of long-lasting adverse reactions to gel fillers used in cosmetic surger

230 p higher antibody responses, experience more adverse reactions to influenza vaccines, and show greate

231 Adverse reactions to insects occur in both human and vet

232 Two participants had serious adverse reactions to intramuscular medroxyprogesterone a

233 None had adverse reactions to IVIg.

234 articles from the taper junction can lead to Adverse Reactions to Metal Debris (ARMD) similar to thos

235 Adverse reactions to oral azoles, drug interactions, and

236 Adverse reactions to peanut were reported in 1.5%, skin

237 (n = 1604), data were collected on reported adverse reactions to peanut, peanut sensitization (serum

238 specimens originating from 59 patients with adverse reactions to polyacrylamide gel, and 54 biopsies

239 include neurodegeneration, high cancer risk, adverse reactions to radiation and chemotherapy, pulmona

240 The prevalence of adverse reactions to radiopharmaceuticals reported in th

241 We assessed all reports of adverse reactions to radiopharmaceuticals that were subm

242 ITPA variants have only been associated with adverse reactions to specific drugs.

243 No adverse reactions to the investigational drug product an

244 The mice showed no adverse reactions to the vaccine, and they were protecte

245 Adverse reactions to the YF vaccine have remained unexpl

246 n associated with reduced efficacy of and/or adverse reactions to therapeutics modified with or conta

247 ugs (NSAIDs) constitute only a subset of all adverse reactions to these drugs, but due to their sever

248 perience treatment-resistant inflammation or adverse reactions to these treatments, and there are cur

249 , approaches to mitigate the risk of serious adverse reactions to this new class of agent have emerge

250 e recorded adverse events, including serious adverse reactions to trial interventions.

251 ll serious adverse events, including serious adverse reactions to trial treatments.

252 len allergies are frequently associated with adverse reactions to various fruits, nuts, or vegetables

253 groups and there were no unexpected serious adverse reactions to xenon during hospital stay.

254 Many patients report adverse reactions to, and may not tolerate, statin thera

255 Adverse reactions typically occur within the first 90 da

256 Patients referred for immediate food adverse reactions underwent a consistent and standardize

257 The most common serious adverse reaction was infection occurring in five infants

258 Systemic adverse reaction was observed in 117 of the 5,954 inject

259 No adverse reaction was observed.

260 One suspected unexpected serious adverse reaction was reported in the MAP group: bone mar

261 The frequency of adverse reactions was similar in both groups, suggesting

262 The adverse reactions we noted were transient anxiety during

263 s Policy Review from the Southern Network on Adverse Reactions, we identify factors preventing the ef

264 ata regarding VST production, infusions, and adverse reactions were compared.

265 No protocol-related serious adverse reactions were confirmed.

266 Adverse reactions were consistent with the previously re

267 Adverse reactions were generally mild but more common wi

268 Almost all treatment-related adverse reactions were graded 1 or 2 (low-grade).

269 Recorded adverse reactions were graded according to World Allergy

270 No adverse reactions were identified in addition to those s

271 Adverse reactions were markedly reduced during OIT escal

272 lly respond to the desensitization protocol, adverse reactions were minor and responded to treatment

273 The most common non-serious adverse reactions were moderate dehydration in one, mild

274 Significant adverse reactions were not detected.

275 olled 102 patients by 7 July 2015; no severe adverse reactions were noted.

276 No adverse reactions were observed related to d-(18)F-FMT.

277 No adverse reactions were observed.

278 Dose reductions for adverse reactions were permitted for pomalidomide and de

279 Adverse reactions were predominantly local patch-site re

280 Abacavir adverse reactions were recently shown to be driven by dr

281 No serious adverse reactions were recorded and other safety measure

282 No adverse reactions were recorded during the tests.

283 Adverse reactions were recorded, and laboratory testing

284 Adverse reactions were recorded.

285 19 serious adverse reactions were reported in 13 patients.

286 No related serious adverse reactions were reported, and the most frequent a

287 t with the underlying disease; no unexpected adverse reactions were reported.

288 th placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported.

289 No suspected unexpected serious adverse reactions were reported.

290 erence 1.21 [0.04 to 2.38], p=0.060), and no adverse reactions were reported.

291 Vaccination was safe and well tolerated; adverse reactions were transient and predominantly mild.

292 and infections, autoimmune diseases or drugs adverse reactions, were excluded.

293 alliation of bone pain, and a low profile of adverse reactions (which are mild and manageable).

294 inquiry delayed notice of ketoacidosis as an adverse reaction, which could have reduced the burden of

295 ght the role of those cytokines in mediating adverse reactions, which is of particular importance for

296 (DILI) is a rare, often difficult-to-predict adverse reaction with complex pathomechanisms.

297 f factors might influence the association of adverse reactions with anti-IgA antibodies, including th

298 mal necrolysis (SJS/TEN) are rare but severe adverse reactions with high mortality.

299 e correlated the presence of immune-mediated adverse reactions with the response pattern.

300 deaths in the United States and hundreds of adverse reactions worldwide, revealing the vulnerability